Skip to content

MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06954337
Enrollment
1750
Registered
2025-05-01
Start date
2025-05-01
Completion date
2027-05-01
Last updated
2026-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Prostate Cancer

Keywords

Telehealth, Cancer Care at Home, 25-055

Brief summary

Many people with cancer spend a lot of time and money traveling to and from the doctor's office for cancer care. MSK's goal is to make getting cancer care easier by cutting down the need to make in-person visits to MSK. MSK is trying to do this through a new option called enhanced telehealth.

Interventions

OTHERExperimental: Enhanced Telehealth (ET)

Patient follows enhanced telehealth practice pattern. As clinically appropriate, patients given option to shift routine care from face-to-face to at-home services available at institution: telehealth visits, home phlebotomy, and educational support for home administration of injection medications

OTHERUsual practice pattern (UPP)

Patient follows usual practice pattern for routine care

Sponsors

Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with breast or prostate cancer at Memorial Sloan Kettering Cancer Center who have had at least 3 prior medical oncology visits.

Exclusion criteria

* Patient is enrolled on a therapeutic clinical trial. * Patients whose primary language is not currently supported by Epic.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of routine face to face medical oncology related visits out of total medical oncology related visits12 monthsall patients who meet eligibility criteria and have completed at least 2 medical oncology visits during the 12 month follow up period will be included for endpoint evaluability during analyses

Countries

United States

Contacts

CONTACTErin Bange, MD, MSCE
bangee@mskcc.org646-422-4680
CONTACTDeborah Schrag, MD, MPH
212-639-5851
PRINCIPAL_INVESTIGATORErin Bange, MD, MSCE

Memorial Sloan Kettering Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 1, 2026